NCT07049575 Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa
| NCT ID | NCT07049575 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Incyte Corporation |
| Condition | Hidradenitis Suppurativa |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2025-11-03 |
| Primary Completion | 2026-12-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 24 participants in total. It began in 2025-11-03 with a primary completion date of 2026-12-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of HS for at least 6 months before screening visit. * Diagnosis of HS (Hurley Stage I, II, III) with a total abscess and inflammatory nodule count of at least 4 and affecting at least 3 distinct anatomical areas at screening and Day 1 visits. * Total estimated treatment BSA \> 20% at screening and baseline. * Agreement to not use topical or systemic antibiotics for treatment of HS during the Maximal Use Treatment Period. * Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol. * Further inclusion criteria apply. Exclusion Criteria: * Current or history of skin condition(s) other than HS that might confound the evaluation of HS; clinically uncontrolled cardiovascular disease; thrombosis; certain cancers; certain infections; severe anemia, thrombocytopenia, or neutropenia; other medical conditions at the discretion of the investigator. * Laboratory values outside of the protocol-defined ranges. * Further exclusion criteria apply.
Contact & Investigator
Incyte Medical Monitor
STUDY DIRECTOR
Incyte Corporation
Frequently Asked Questions
Who can join the NCT07049575 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, up to 75 Years, studying Hidradenitis Suppurativa. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07049575 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07049575 currently recruiting?
Yes, NCT07049575 is actively recruiting participants. Contact the research team at medinfo@incyte.com for enrollment information.
Where is the NCT07049575 trial being conducted?
This trial is being conducted at Phoenix, United States, Fountain Valley, United States, Northridge, United States, Orange, United States and 11 additional locations.
Who is sponsoring the NCT07049575 clinical trial?
NCT07049575 is sponsored by Incyte Corporation. The principal investigator is Incyte Medical Monitor at Incyte Corporation. The trial plans to enroll 24 participants.